{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:53:30Z","timestamp":1791212010038,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Neurotrophic keratopathy (NK) is a serious ocular surface disease that develops due to a reduction or loss of corneal innervation. Conventional therapeutic approaches, such as the use of artificial tears and autologous serum, primarily serve as symptomatic relief measures and do not target the underlying neurodegenerative process. The introduction of recombinant human nerve growth factor (rhNGF, cenegermin) has marked the first disease-modifying pharmacological therapy for NK, providing evidence of enhanced epithelial healing and improved corneal sensitivity. In recent years, with biotechnological advancements and the emergence of genetic therapy strategies, the importance of pathophysiology-oriented treatments in NK therapy has increased. The objective of this review is to offer an analysis of the management of NK in the context of recent pharmacological and biotechnological advancements in the light of current literature. This review aims to provide an integrated and pathophysiology-oriented synthesis of NK management, uniquely bridging pharmacological treatments with emerging biotechnological strategies including gene therapy, cell-based approaches, and novel drug delivery systems.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3092_25","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:00:14Z","timestamp":1787554814000},"page":"S333-S339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["New pharmacological and biotechnological approaches for the treatment of neurotrophic keratopathy: From growth factors to gene therapy"],"prefix":"10.4103","volume":"74","author":[{"given":"Mukaddes Damla","family":"Ciftci","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Gurdal","sequence":"additional","affiliation":[{"name":"Ocular Surface Research Laboratory, Faculty of Medicine, Ege University, Izmir, T\u00fcrkiye"},{"name":"Ege University Technopark, LimbuStem R&D Medical Products, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem B","family":"Selver","sequence":"additional","affiliation":[{"name":"Ocular Surface Research Laboratory, Faculty of Medicine, Ege University, Izmir, T\u00fcrkiye"},{"name":"Ege University Technopark, LimbuStem R&D Medical Products, Izmir, T\u00fcrkiye"},{"name":"Department of Ophthalmology, Faculty of Medicine, Ege University, Izmir, T\u00fcrkiye"},{"name":"Department of Stem Cell, Institute of Health Sciences, Ege University, Izmir, T\u00fcrkiye"},{"name":"Cord Blood-Cell Tissue Application and Research Center, Ege University, Izmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R1-20261005","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.eye.6700616","article-title":"Neurotrophic keratitis","volume":"17","author":"Bonini","year":"2003","journal-title":"Eye (Lond)"},{"key":"R2-20261005","first-page":"461","article-title":"Sensory and sympathetic innervation of the mammalian cornea. A retrograde tracing study","volume":"30","author":"Marfurt","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-20261005","first-page":"692","article-title":"Neurotrophic factors in the human cornea","volume":"41","author":"You","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20261005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","article-title":"Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes","volume":"18","author":"Saad","year":"2020","journal-title":"Ocul Surf"},{"key":"R6-20261005","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1007\/s10792-023-02866-0","article-title":"Herpes simplex virus keratitis: Electronic medical records driven big data analytics report from a tertiary eye institute of South India","volume":"43","author":"Das","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R7-20261005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4103\/ijo.IJO_710_19","article-title":"Big data and the eyeSmart electronic medical record system-An 8-year experience from a three-tier eye care network in India","volume":"68","author":"Das","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R8-20261005","first-page":"2623","article-title":"Efficacy of treatments for neurotrophic keratopathy: A systematic review and meta-analysis","volume":"260","author":"Roumeau","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20261005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (Cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"R10-20261005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40265-025-02147-3","article-title":"Current and emerging therapeutic strategies for the management of neurotrophic keratitis","volume":"85","author":"Lacorzana","year":"2025","journal-title":"Drugs"},{"key":"R11-20261005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R12-20261005","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3390\/jcm8091478","article-title":"Blood-based treatments for severe dry eye disease: The need of a consensus","volume":"8","author":"Bernabei","year":"2019","journal-title":"J Clin Med"},{"key":"R13-20261005","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/ICO.0000000000001297","article-title":"Use of topical insulin to treat refractory neurotrophic corneal ulcers","volume":"36","author":"Wang","year":"2017","journal-title":"Cornea"},{"key":"R14-20261005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jns5.12044","article-title":"Repeated monitoring of corneal nerves by confocal microscopy as an index of peripheral neuropathy in type-1 diabetic rodents and the effects of topical insulin","volume":"18","author":"Chen","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"R15-20261005","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4103\/IJO.IJO_17_23","article-title":"Contact lenses for the treatment of ocular surface diseases","volume":"71","author":"Sharma","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R16-20261005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PRS.0b013e3181904d3a","article-title":"Corneal neurotization: A novel solution to neurotrophic keratopathy","volume":"123","author":"Terzis","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R17-20261005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajo.2020.07.003","article-title":"Direct versus indirect corneal neurotization for the treatment of neurotrophic keratopathy: A multicenter prospective comparative study","volume":"220","author":"Fogagnolo","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R18-20261005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/IOP.0000000000001586","article-title":"Clinical and morphologic outcomes of minimally invasive direct corneal neurotization","volume":"36","author":"Wisely","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R19-20261005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ICU.0000000000001138","article-title":"Corneal neurotization for the treatment of neurotrophic keratopathy","volume":"36","author":"Hubschman","year":"2025","journal-title":"Curr Opin Ophthalmol"},{"key":"R20-20261005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/ICO.0000000000001315","article-title":"In vivo confocal microscopy reveals corneal reinnervation after treatment of neurotrophic keratopathy with corneal neurotization","volume":"37","author":"Fung","year":"2018","journal-title":"Cornea"},{"key":"R21-20261005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/SAP.0000000000003117","article-title":"Corneal neurotization: A meta-analysis of outcomes and patient selection factors","volume":"88","author":"Swanson","year":"2022","journal-title":"Ann Plast Surg"},{"key":"R23-20261005","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2147\/OPTH.S185184","article-title":"Update on cenegermin eye drops in the treatment of neurotrophic keratitis","volume":"13","author":"Sheha","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R24-20261005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/1570159X13666150403231920","article-title":"Nerve growth factor: A focus on neuroscience and therapy","volume":"13","author":"Aloe","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"R25-20261005","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"R26-20261005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40265-020-01289-w","article-title":"Cenegermin: A review in neurotrophic keratitis","volume":"80","author":"Deeks","year":"2020","journal-title":"Drugs"},{"key":"R27-20261005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2010.05471.x","article-title":"Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4","volume":"1194","author":"Dunn","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R28-20261005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/bjo.2007.130013","article-title":"Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy","volume":"92","author":"Yamada","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R29-20261005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10384-007-0480-z","article-title":"Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1","volume":"51","author":"Nishida","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"R30-20261005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.exer.2017.10.006","article-title":"The role of hepatocyte growth factor in corneal wound healing","volume":"166","author":"Miyagi","year":"2018","journal-title":"Exp Eye Res"},{"key":"R31-20261005","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ymthe.2017.04.020","article-title":"Hepatocyte growth factor suppresses inflammation and promotes epithelium repair in corneal injury","volume":"25","author":"Omoto","year":"2017","journal-title":"Mol Ther"},{"key":"R32-20261005","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease","volume":"41","author":"Wirta","year":"2022","journal-title":"Cornea"},{"key":"R33-20261005","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/archophthalmol.2009.270","article-title":"Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus","volume":"127","author":"Zagon","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R34-20261005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ICL.0000000000000229","article-title":"Topical coenzyme Q10 eye drops as an adjuvant treatment in challenging refractory corneal ulcers: A case series and literature review","volume":"43","author":"Gumus","year":"2017","journal-title":"Eye Contact Lens"},{"key":"R35-20261005","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.ophtha.2006.12.014","article-title":"Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis","volume":"114","author":"Yoon","year":"2007","journal-title":"Ophthalmology"},{"key":"R36-20261005","first-page":"347","article-title":"Clinical evaluation of allogeneic eye drops from cord blood platelet lysate","volume":"19","author":"Samarkanova","year":"2021","journal-title":"Blood Transfus"},{"key":"R37-20261005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17460751.2025.2472578","article-title":"Beyond transplants: Current and future therapeutic potential of amniotic membrane extract (AME) in ophthalmology","volume":"20","author":"Korkmaz","year":"2025","journal-title":"Regen Med"},{"key":"R38-20261005","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s10792-021-01856-4","article-title":"Amniotic membrane extract eye drops for ocular surface diseases: Use and clinical outcome in real-world practice","volume":"41","author":"Sabater-Cruz","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R39-20261005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10561-021-09962-4","article-title":"Amniotic membrane extract eye drops: A new approach to severe ocular surface pathologies","volume":"23","author":"P\u00e9rez","year":"2022","journal-title":"Cell Tissue Bank"},{"key":"R40-20261005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00044011-200828090-00001","article-title":"Therapeutic use of nicergoline","volume":"28","author":"Winblad","year":"2008","journal-title":"Clin Drug Investig"},{"key":"R41-20261005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1167\/iovs.08-2037","article-title":"Effects of nicergoline on corneal epithelial wound healing in rat eyes","volume":"50","author":"Kim","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R42-20261005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/ICO.0000000000000348","article-title":"Treatment of neurotrophic keratopathy with nicergoline","volume":"34","author":"Lee","year":"2015","journal-title":"Cornea"},{"key":"R43-20261005","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1080\/09273948.2021.1976214","article-title":"Use of nicergoline as adjunctive treatment of neurotrophic keratitis in routine clinical practice: A case series","volume":"30","author":"Miguel-Escuder","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R45-20261005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jtos.2020.09.007","article-title":"The molecular basis of neurotrophic keratopathy: Diagnostic and therapeutic implications. A review","volume":"19","author":"Ruiz-Lozano","year":"2021","journal-title":"Ocul Surf"},{"key":"R46-20261005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13353-025-00973-5","article-title":"Gene therapy strategies in ophthalmology-An overview of current developments and future prospects","volume":"67","author":"Krajewska","year":"2026","journal-title":"J Appl Genet"},{"key":"R47-20261005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jtos.2024.09.010","article-title":"Preventing and treating neurotrophic keratopathy by a single intrastromal injection of AAV-mediated gene therapy","volume":"34","author":"Cong","year":"2024","journal-title":"Ocul Surf"},{"key":"R48-20261005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14712598.2023.2175605","article-title":"Applications of mesenchymal stem cells in ocular surface diseases: Sources and routes of delivery","volume":"23","author":"Soleimani","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R49-20261005","first-page":"1","article-title":"The role of limbal stem cells on neurotrophic cornea","author":"Ciftci","year":"2025","journal-title":"Clin Exp Optom"},{"key":"R50-20261005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jtos.2025.05.009","article-title":"Safety of subconjunctival injection of mesenchymal stromal cells in persistent corneal epithelial disease-A phase 1b clinical trial","volume":"38","author":"Tu","year":"2025","journal-title":"Ocul Surf"},{"key":"R51-20261005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jtos.2023.09.008","article-title":"Intrastromal versus subconjunctival injection of mesenchymal stem\/stromal cells for promoting corneal repair","volume":"30","author":"Soleimani","year":"2023","journal-title":"Ocul Surf"},{"key":"R52-20261005","doi-asserted-by":"crossref","first-page":"sxaf048","DOI":"10.1093\/stmcls\/sxaf048","article-title":"Clinical evidence and critical review of mesenchymal stromal cells for corneal and ocular surface diseases","volume":"43","author":"Tu","year":"2025","journal-title":"Stem Cells"},{"key":"R53-20261005","doi-asserted-by":"crossref","first-page":"121090","DOI":"10.1016\/j.ijpharm.2021.121090","article-title":"Advances and challenges in the nanoparticles-laden contact lenses for ocular drug delivery","volume":"608","author":"Maulvi","year":"2021","journal-title":"Int J Pharm"},{"key":"R54-20261005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1167\/tvst.13.6.12","article-title":"Development and characterization of a photocrosslinkable, chitosan-based, nerve growth factor-eluting hydrogel for the ocular surface","volume":"13","author":"Kanu","year":"2024","journal-title":"Transl Vis Sci Technol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3092_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:01:26Z","timestamp":1791208886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3092_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":51,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3092_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2025-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}